NCT06222892View on ClinicalTrials.gov

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

December 17, 2024

Study Completion Date

December 30, 2024

Conditions
Cough
Interventions
DRUG

Camlipixant

Camlipixant will be administered.

Trial Locations (3)

32809

GSK Investigational Site, Orlando

33136

GSK Investigational Site, Miami

78215

GSK Investigational Site, San Antonio

All Listed Sponsors
lead

Bellus Health Inc. - a GSK company

INDUSTRY

NCT06222892 - A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age | Biotech Hunter | Biotech Hunter